Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVerma, Akashen
dc.contributor.authorChopra, Akhilen
dc.contributor.authorLee, Yeo W.en
dc.contributor.authorBharwani, Lavina D.en
dc.contributor.authorAsmat, Atasha B.en
dc.contributor.authorAneez, Dokeu B. A.en
dc.contributor.authorAkbar, Fazuludeen A.en
dc.contributor.authorLim, Albert Y. H.en
dc.contributor.authorChotirmall, Sanjay Hareshen
dc.contributor.authorAbisheganaden, Johnen
dc.identifier.citationVerma, A., Chopra, A., Lee, Y. W., Bharwani, L. D., Asmat, A. B., Aneez, D. B. A., et al. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. Current Drug Discovery Technologies, 13(2), 68-76.en
dc.description.abstractBackground and Objective: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) are effective against lung adenocarcinoma. However, limited data is available assessing the effectiveness of EGFR-TKI use in preventing re-accumulation of MPE. To our knowledge, there is no literature on comparison of talc pleurodesis with EGFR-TKIs alone on re-accumulation of MPE in Asian population. We investigated if EGFR-TKI therapy for advanced lung adenocarcinoma with malignant pleural effusion (MPE) is also successful in preventing pleural fluid re-accumulation following initial drainage. Methods: An observational cohort study of patients with lung adenocarcinoma and MPE in the year 2012 was conducted. Results: 70 patients presented with MPE from lung adenocarcinoma. Fifty six underwent EGFR mutation testing of which 39 (69.6%) had activating EGFR mutation and 34 (87.1%) received TKI. 20 were managed by pleural fluid drainage only whereas 14 underwent talc pleurodesis following pleural fluid drainage. Time taken for the pleural effusion to re-accumulate in those with and without pleurodesis was 9.9 vs. 11.7 months, p=0.59 respectively. More patients (n=10, 25.6%) with activating EGFR mutation presented with complete opacification (white-out) of the hemithorax compared to none without activating EGFR mutation (p=0.02). Conclusion: In TKI eligible patients, early talc pleurodesis may not confer additional benefit in preventing re-accumulation of pleural effusion and may be reserved for non-adenocarcinoma histology, or EGFR negative adenocarcinoma. Complete opacification of the hemithorax on presentation may serve as an early radiographic signal of positive EGFR mutation status.en
dc.relation.ispartofseriesCurrent Drug Discovery Technologiesen
dc.rights© 2016 Bentham Science Publishersen
dc.subjectLung canceren
dc.titleCan EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinomaen
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en
item.fulltextNo Fulltext-
Appears in Collections:LKCMedicine Journal Articles

Citations 20

Updated on Dec 5, 2022

Page view(s) 50

Updated on Dec 9, 2022

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.